GF-1003
Asset
An mRNA formulation delivers SIRT6c to dermal fibroblasts.
- Stage
- Preclinical
- Modality
- mRNA
- Target
- SIRT6
- 0
- Indications
- 0
- Trials
- 1
- Developer
Indications
1No named disease
Preclinical, genflowbio.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors3
Every asset’s record: target, stage, trials and the evidence behind it.